A brief slidedoc that reviews why we focus on both the cancer we can see and the potential cancer we can't when we shape our treatment recommendations in lung cancer and many other cancers.
Radiotherapy and Immunotherapy Improve Metastatic Lung Cancer OutcomesLaura Lyn Jacimore
A radiation oncologist, Laura Lyn Jacimore works at UNC Nash Health Care System in Rocky Mount, North Carolina, where she consults with physicians to administer radiotherapy treatments to people with cancer. Laura Lyn Jacimore is also a member of the American Society of Therapeutic Radiation Oncology (ASTRO), and regularly attends its annual meetings.
Light Therapy: A Huge Step forward for Prostate Cancer TreatmentRubySteele
Prostate cancer may be the second most common cancer in men in the United States, but scientists from the University College London are giving men with the disease a reason to hope for a better tomorrow.
Radiotherapy and Immunotherapy Improve Metastatic Lung Cancer OutcomesLaura Lyn Jacimore
A radiation oncologist, Laura Lyn Jacimore works at UNC Nash Health Care System in Rocky Mount, North Carolina, where she consults with physicians to administer radiotherapy treatments to people with cancer. Laura Lyn Jacimore is also a member of the American Society of Therapeutic Radiation Oncology (ASTRO), and regularly attends its annual meetings.
Light Therapy: A Huge Step forward for Prostate Cancer TreatmentRubySteele
Prostate cancer may be the second most common cancer in men in the United States, but scientists from the University College London are giving men with the disease a reason to hope for a better tomorrow.
Caren Stalburg, MD, MA presented to the 2016 annual Snow meeting of the Michigan Section of the American Congress of Obstetricians and Gynecologists (ACOG) about her program to train Michigan providers about the new Breast Density Notification Law (http://www.midensebreasts.org/).
Dr. Stalburg is Division Chief and Clinical Assistant Professor in the Division of Professional Education in the Department of Learning Health Sciences and Assistant Professor of Obstetrics and Gynecology in the University of Michigan Medical School.
Learn about the process of radiation therapy to treat soft tissue sarcoma, and how new radiation technology has improved treatment of the disease.
This presentation was given by Elizabeth H. Baldini, MD, MPH, radiation oncology director for the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute. It was originally presented as part of the "15 Years of GIST/Soft Tissue Sarcoma Symposium," held on Sept. 12, 2015 at Dana-Farber in Boston, Mass.
A complete guide from Lyfboat on cancer treatment signs, symptoms, diagnosis and treatment options...
See more at : https://www.lyfboat.com/best-cancer-hospitals-costs-india-thailand-malaysia-uae/
What is the value of maintenance therapy in advanced NSCLC, and who should ge...H. Jack West
Dr. Jack West reviews the rationale for maintenance therapy in advanced NSCLC, what the evidence shows about its value, the limitations, and thoughts on which patients should or should not pursue it.
In the interior design showcase at the Cleveland Botanical Gardens, more than a dozen local designers created room vignettes inspired by or accented with orchids. Here, we share several ways the experts decorated with orchids so you can feel inspired to bring the beauty of orchids into your home.
Dinámica económica, desarrollo productivo exportador de lambayequeAREX Lambayeque
Ponencia realizada en elmarco del DÍA DEL EXPORTADOR, el pasao 9 de noviembre del 2016; a cargo del Mg. Eduardo Elera Hurtado, especialista de Comercio Exterior de la GERCETUR.
Caren Stalburg, MD, MA presented to the 2016 annual Snow meeting of the Michigan Section of the American Congress of Obstetricians and Gynecologists (ACOG) about her program to train Michigan providers about the new Breast Density Notification Law (http://www.midensebreasts.org/).
Dr. Stalburg is Division Chief and Clinical Assistant Professor in the Division of Professional Education in the Department of Learning Health Sciences and Assistant Professor of Obstetrics and Gynecology in the University of Michigan Medical School.
Learn about the process of radiation therapy to treat soft tissue sarcoma, and how new radiation technology has improved treatment of the disease.
This presentation was given by Elizabeth H. Baldini, MD, MPH, radiation oncology director for the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute. It was originally presented as part of the "15 Years of GIST/Soft Tissue Sarcoma Symposium," held on Sept. 12, 2015 at Dana-Farber in Boston, Mass.
A complete guide from Lyfboat on cancer treatment signs, symptoms, diagnosis and treatment options...
See more at : https://www.lyfboat.com/best-cancer-hospitals-costs-india-thailand-malaysia-uae/
What is the value of maintenance therapy in advanced NSCLC, and who should ge...H. Jack West
Dr. Jack West reviews the rationale for maintenance therapy in advanced NSCLC, what the evidence shows about its value, the limitations, and thoughts on which patients should or should not pursue it.
In the interior design showcase at the Cleveland Botanical Gardens, more than a dozen local designers created room vignettes inspired by or accented with orchids. Here, we share several ways the experts decorated with orchids so you can feel inspired to bring the beauty of orchids into your home.
Dinámica económica, desarrollo productivo exportador de lambayequeAREX Lambayeque
Ponencia realizada en elmarco del DÍA DEL EXPORTADOR, el pasao 9 de noviembre del 2016; a cargo del Mg. Eduardo Elera Hurtado, especialista de Comercio Exterior de la GERCETUR.
Blogging - the why the how and the method for businesses and individualsPaul Boomer
You'll learn why it's important to blog and create a platform for your business. You'll also learn what to expect as you start a blog. Additionally you'll learn ways provide reasons for people to come back to your blog site as they learn you're the expert in the ___________ field.
Year over year, consumer research and surveys show how the Just Add Ice Orchids® brand continues to grow and become better known across various demographics and geography. This report highlights many interesting value points that were collected in the recently
completed second annual Consumer Survey.
Key Points:
Brand awareness is growing in younger demographics
Customers are overwhelmingly happy with their purchase
Customer engagement results in repeat orchid purchases
Economic factors have little impact on sales
Lungs are a very sensitive pair of organs to treat and may not respond to treatments easily. A comprehensive study of the patient’s stage and pre-existing health conditions are taken into account to design the most effective approach for treatment. Consult best lung cancer specialist in delhi ncr Dr. Manish Singhal.
Dr. Pk Das Is one of the famous and highly qualified doctor of cancer. He is a cervical cancer specialist in Delhi NCR. Consult Dr.PK Das for all cervical cancer related queries.
Dr. Pramoj Jindal is one of the few-trained thoracic onco-surgeon (cancer surgeon) in India. He has been practicing laparoscopic/foregut surgery for over 15 years and thoracic surgery over 5 years. Trained at various world leading thoracic surgical centers of the world. He has been working in the prestigious Sir Ganga Ram Hospital, New Delhi since year 2000. He has tried to bring the quality of world-class surgical techniques into India in thoracic surgery. [www.drpramojjindal.com/]
Lung Cancer Awareness By Epillo Health Systems EpilloHealth
November is officially lung cancer awareness month. The event started back in 1995 as lung cancer awareness day. As the lung cancer community and the lung cancer movement grew, the awareness activities increased and the day matured into Lung Cancer awareness month. This is a brief presentation for the awareness on Lung Cancer Awareness by the team Epillo.
Dr. Lalit Banswal is the Best Thoracic Cancer Doctor in Undri, Pune. We offer best treatment for thoracic cancer which include lung cancer. Consult Now to Know More About The Treatment.
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer MedicineH. Jack West
The concept of personalized or precision medicine is hot enough that President Obama is launching initiatives for it, but how close is it to moving beyond hype?
Here are 3 key steps we need to attain to know that personalized medicine, particularly in the world of cancer care, isn't just delivering false hope for most patients.
Best of ASCO Metastatic Non-Small Cell Lung CancerH. Jack West
Dr. Jack West's presentation on highlights in advanced non-small cell lung cancer from ASCO 2014, focusing on new agents ramucirumab and necitumumab for broad NSCLC populations, crizotinib and ceritinib for ALK-positive NSCLC, EGFR inhibitor-options of afatinib and bevacizumab added to erlotinib for first line treatment of EGFR mutation-positive NSCLC, and AZD9291 or CO1686 for EGFR mutation-positive patients with acquired resistance.
10 Key ASCO 2014 Presentations in Lung CancerH. Jack West
Dr. Jack West offers a list of 10 of the most important, timely abstract presentations in lung cancer, both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), at the annual ASCO 2014 conference.
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...H. Jack West
Dr. Jack West reviews the evolution of new treatment options for advanced NSCLC that have steadily improved survival. This progress has been incremental but now means that an ever-growing proportion of patients with advanced NSCLC have a realistic promise of potentially living several years after their diagnosis and the start of treatment. Note that this presentation does not address advances in immunotherapy, which were covered in a separate talk at the same conference at which Dr. West delivered this presentation.
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...H. Jack West
Dr. Jack West reviews the importance of assessing the degree of progression when interpreting whether to change treatment of a cancer. It is important to ask not only whether a cancer has progressed, but HOW it has done so, and how much?
Key Clinical Implications of how a Cancer EvolvesH. Jack West
Cancer adapts and evolves over time and under the selective pressure of systemic treatment, becoming increasingly resistant over time. This brief slidedoc fo summarizes key points in how cancer adaptation leads to resistance and changes our treatment recommendations.
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...H. Jack West
Discussion of how online patient communities and social media are changing relationships between engaged patients and oncologists, improving quality of cancer care.
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and LucanixH. Jack West
Update of results and current clinical trials of vaccines for lung cancer, including MAGE-A3, Stimuvax, and Lucanix for stage I-III non-small cell lung cancer. @JackWestMD, @CancerGRACE cancerGRACE.org
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...H. Jack West
This is a presentation I did for a meeting on new general management of acquired resistance in 2014, including the concept of local therapy for limited progression, and new treatment approaches and new agents for this setting. It features discussion of several of the most important trials.
West egfr mutation acquired resistanceH. Jack West
Review by Dr. H. Jack West of current understanding of mechanisms behind and emerging treatment options for patients with advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors after a good initial response.
Dr. Jack West Oncology 2.0, to WA AG's OfficeH. Jack West
Dr. H. Jack West, medical oncologist and Founder/CEO of Global Resource for Advancing Cancer Education (GRACE, www.CancerGRACE.org), spoke to WA state Attorney General's office about the changing landscape of cancer care and how the internet and specifically online patient communities and education will become disruptive in changing the patient/physician dynamic.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Treating Invisible Disease: How the Probability of Disease We Can't See Changes Our Treatment Strategy in Lung Cancer
1. Treating Invisible Disease:
How the Probability of Disease We Can’t See
Changes Our Treatment Strategy in Lung Cancer
H. Jack West, MD
2. Why should we care about cancer we can’t see?
• Cancer risk is a combination of that from visible disease and
potential/presumed risk posed by disease we cannot see.
• The balance of our focus on visible vs. invisible disease shapes a
huge amount of our treatment recommendations for different
settings in lung cancer (and other cancers).
• The main threat of recurrence in early stage, and the reason
metastatic disease is considered incurable, is a product of invisible,
micrometastatic cancer.
Visible Cancer
Invisible
(micrometastatic)
Cancer
Visible Cancer
Invisible
Cancer
Early Stage NSCLC
Visible
Cancer
Invisible Cancer
Advanced NSCLC or SCLC
3. Assessing Risk of Invisible/
Micrometastatic Disease
Higher risk
• Significant progression over scans prior
to diagnosis
• Adenocarcinoma, small cell lung cancer
• Higher metabolic uptake (SUV) on PET
• Higher grade/more poorly
differentiated cancer
• Higher stage
– Larger primary tumor
– Higher nodal stage
– Larger number of nodes involved
Lower risk
• Squamous cell, bronchiololalveolar
carcinoma
• Lower metabolic uptake (SUV) on PET
• Lower grade/well differentiated cancer
• Minimal progression over scans prior to
diagnosis
• Lower stage
– Smaller primary tumor
– Lower nodal stage
– Few nodes involved
4. Local Therapy is Leading Treatment for
Limited Visible Cancer
• Surgery is the cornerstone of
treatment for early stage NSCLC.
• Radiation is favored for early stage
NSCLC in patients who cannot
tolerate surgery.
• Traditionally, surgery has been
favored for disease that is felt most
likely to be limited to what you can
see (if tolerable for patient).
• As risk of invisible disease relative
to visible disease increases,
radiation becomes more favored
over surgery because radiation
“casts a wider net” to treat regional
invisible disease than surgery.
5. Systemic therapy can treat both visible and
invisible/micrometastatic disease
• Systemic (whole body) treatments like
chemotherapy (usually IV) or targeted
therapies (oral or IV) go throughout the
bloodstream to treat cancer everywhere*
• It is used in many lung cancer settings.
– For potentially curable lung cancer, it is given to
reduce risk of micrometastatic disease causing
recurrence after surgery and/or radiation given
to eradicate localized disease.
– In locally advanced (stage III) NSCLC, it is given
to make radiation more effective within the
radiation field, and also to treat invisible
disease outside of the radiation field.
– For advanced lung cancer (NSCLC or SCLC), it is
given to simultaneously shrink visible disease
and to inhibit progression with new areas of
disease caused by invisible micrometastases.
*systemic therapies often don’t get into
the central nervous system (CNS) very
well because of the blood-brain barrier
6. Why We Can’t Consider Advanced NSCLC
Cured Even if We Can’t See it
• Once someone has metastatic disease (including spread to fluid outside of
the lungs), this indicates that cancer can spread throughout the body and
will almost invariably recur, even if all of the visible disease is removed.
• Having metastatic lung cancer (or
many other cancers) is like having a
lawn full of dandelions. Just as pulling
each dandelion won’t eradicate the
problem, treating every individual
lesion in the body is not a cure,.
• The invisible cancer, like dandelion
seeds, are destined to cause new
areas to pop up.
• The goal is to control invisible disease
along with visible disease
simultaneously.
7. Getting to NED: The Goals of Treatment
for Advanced Lung Cancer
• Because we can’t feasibly eradicate all
invisible disease, our goals for patients with
advanced lung cancer involve balancing
several factors.
– We want to shrink the visible cancer as much
as possible, with the ideal case being “NED”:
No Evidence of Disease
– We want to prevent both existing lesions from
growing and from invisible, micrometastatic
disease progressing into new visible lesions.
This boils down to maximizing time before
disease shows evidence of progression.
– We want to do control the visible and invisible
disease for as long as possible and with the
best tolerated treatment possible.
A normal chest CT. Even if we
can’t realistically expect “NED”
status to last forever in someone
with advanced lung cancer, it’s
great to see and associated with
a very favorable prognosis.